Immunotherapy

It does not attack the tumour directly — it releases your own immune system so that it can recognise it.

What it is

Immunotherapy does not attack the tumour directly. It releases the patient’s own immune system so that it can recognise and act on the tumour.

Many tumours survive precisely because they have learned to apply the brake on T cells. Checkpoint inhibitors take that brake off.

How it works

The most widely used agents target the PD-1 / PD-L1 and CTLA-4 pathways. By blocking the inhibitory signal, they let T cells recognise cancer cells as foreign.

Because the effect works through the immune system, a response can take time to become visible — but when it is achieved, in some cases it lasts.

Who it is for

Immunotherapy is part of treatment for several malignancies, including lung, triple-negative breast, stomach and oesophageal cancer, as well as tumours with microsatellite instability (MSI-high) regardless of their organ of origin.

PD-L1 expression and MSI status help predict who is more likely to benefit.

What to expect

It is given intravenously in a day unit, every two to six weeks depending on the agent. The infusion itself is short and most people return to their activities the same day.

Side effects and management

Most people tolerate immunotherapy well. Side effects, when they occur, are of a different nature: they arise from an immune system that has become more active and may affect healthy tissue — most often the skin, thyroid, bowel or liver.

These reactions are managed effectively when recognised early. That is why you are asked to report new symptoms promptly, even ones that seem minor — persistent diarrhoea or unusual fatigue is worth a phone call.

How the treatment is chosen

None of these treatments is “better” than the others in the abstract. The choice comes from the biology of the specific tumour, the stage, previous treatment, other conditions and — not least — what matters to you.

You will be told why this treatment is proposed rather than another, what it is expected to achieve, and what it will mean in practice for your daily life. If something is unclear, asking is always welcome — and so is a second opinion.

Frequently asked questions

Does immunotherapy work for everyone?

No. Some patients benefit substantially while others do not respond. Biomarkers help select those with the best chance, but they do not predict with certainty.

How long does treatment last?

It depends on the indication. In some settings it is given for a defined period after surgery; in others it continues for as long as it helps and is tolerated. The plan is discussed from the outset.